Bio-Techne Corporation has entered into a definitive merger agreement to be acquired by Merck KGaA, Darmstadt, Germany. The all-cash transaction values Bio-Techne at an enterprise value of approximately $11.3 billion and is intended to strengthen Merck KGaA's position in high-growth life sciences markets.
Key Details
- Transaction Terms: Merck KGaA will acquire all outstanding shares of Bio-Techne for $73.00 per share in cash, a 36% premium to the company's one-month volume-weighted average price.
- Timeline & Approvals: The acquisition is expected to close in late 2026 or early 2027, subject to customary closing conditions, including regulatory approvals and the approval of Bio-Techne's shareholders.
- Financial Outlook: The transaction is expected to be immediately accretive to sales growth and EBITDA margin. Merck KGaA anticipates realizing approximately €140 million in annual cost synergies by the third year after closing.